Repare Therapeutics Q3 2023 Earnings Report
Key Takeaways
Repare Therapeutics reported financial results for the third quarter ended September 30, 2023. The company highlighted the advancement of its pipeline, particularly the Phase 1 MYTHIC trial evaluating lunresertib. Initial data from the trial showed early efficacy signals across multiple tumor types, most notably in gynecological tumors, along with a favorable safety and tolerability profile.
Presented positive initial data from the Phase 1 MYTHIC trial evaluating lunresertib alone and in combination with camonsertib.
Reported an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors in the MYTHIC trial.
Advanced lunresertib (RP-6306) for the treatment of molecularly selected advanced solid tumors.
Roche has included a camonsertib-based arm in its Phase 2 TAPISTRY trial.
Repare Therapeutics
Repare Therapeutics
Forward Guidance
Repare expects to report additional combination therapy data from the expansion cohorts of the MYTHIC trial in the second half of 2024. Repare expects to report initial data from its ongoing Phase 1 MINOTAUR trial evaluating lunresertib in combination with FOLFIRI (NCT05147350) in the first half of 2024. Additionally, the Company expects to report initial updated data from its ongoing Phase 1 MAGNETIC trial evaluating lunresertib in combination with gemcitabine (NCT05147272) in the second half of 2024.